Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pd-1 Inhibitors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT07537985
What this trial is testing

Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment

Who this might be right for
Hepatocellulcar Carcinoma
Sun Yat-sen University 200
Not applicableStudy completedNCT06248554
What this trial is testing

Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation

Who this might be right for
Hepatocellular Carcinoma
Chen Xiaoping 251
Not applicableLooking for participantsNCT06333561
What this trial is testing

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Who this might be right for
Hepatocellular CarcinomaLenvatinibPD-1 Inhibitor+1 more
Sun Yat-sen University 300
Early research (Phase 1)Ended earlyNCT03425461
What this trial is testing

Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

Who this might be right for
Metastatic MelanomaStage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7+3 more
Jonsson Comprehensive Cancer Center 6
Testing effectiveness (Phase 2)UnknownNCT05453383
What this trial is testing

Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib

Who this might be right for
Hepatocellular Cancer
Shen Feng 30
Not applicableStudy completedNCT02827344
What this trial is testing

PDL-1 Expression on Circulating Tumor Cells in Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer
University Hospital, Toulouse 216
Testing effectiveness (Phase 2)Study completedNCT07720011
What this trial is testing

Interim PET/CT-adapted Use of PD-1 Inhibitor Combined With De-escalated Chemotherapy-AVD in Classic Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin Lymphoma
Peking University People's Hospital 130
Testing effectiveness (Phase 2)UnknownNCT04848597
What this trial is testing

PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP

Who this might be right for
Cancer of Unknown Primary
Fudan University 48
Testing effectiveness (Phase 2)UnknownNCT05222035
What this trial is testing

PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure

Who this might be right for
PD-1 InhibitorG-CSF
Sun Yat-sen University 68
Not applicableUnknownNCT04063449
What this trial is testing

Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC

Who this might be right for
Non-squamous Non-small Cell Lung Cancer
Dong Wang 170
Testing effectiveness (Phase 2)UnknownNCT04399785
What this trial is testing

Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Xingchen Peng 34
Early research (Phase 1)WithdrawnNCT05472506
What this trial is testing

Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer

Who this might be right for
Head and Neck Squamous Cell CarcinomaHead and Neck CancerHead Cancer+3 more
Ikena Oncology
Testing effectiveness (Phase 2)Looking for participantsNCT07394387
What this trial is testing

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

Who this might be right for
Triple Negative Breast Cancer (TNBC)
The First Affiliated Hospital with Nanjing Medical University 58
Testing effectiveness (Phase 2)UnknownNCT04831658
What this trial is testing

A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma

Who this might be right for
Primary Central Nervous System Lymphoma
Mingzhi Zhang 40
Testing effectiveness (Phase 2)UnknownNCT06156891
What this trial is testing

PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC

Who this might be right for
Oropharyngeal Cancer
Fudan University 60
Testing effectiveness (Phase 2)Study completedNCT02306850
What this trial is testing

Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma

Who this might be right for
Unresectable Malignant NeoplasmMelanomaMetastatic Melanoma+2 more
St. Louis University 10
Testing effectiveness (Phase 2)Looking for participantsNCT07330050
What this trial is testing

WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Tianjin Medical University Cancer Institute and Hospital 31
Testing effectiveness (Phase 2)Ended earlyNCT05920408
What this trial is testing

Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours

Who this might be right for
Advanced Solid Tumours
Exscientia AI Limited 6
Testing effectiveness (Phase 2)Study completedNCT04696055
What this trial is testing

Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

Who this might be right for
Hepatocellular Carcinoma
Bayer 95
Testing effectiveness (Phase 2)Study completedNCT03977467
What this trial is testing

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

Who this might be right for
Non-Small Cell Lung CancerSolid Tumor
SCRI Development Innovations, LLC 46
Next Page